Conclusion: Final Thoughts on Managing Hodgkin Lymphoma

Panelists: Jonathan W. Friedberg, MD, University of Rochester; Paul A. Hamlin, MD, MSKCC;
Craig H. Moskowitz, MD, MSKCC; Lauren C. Pinter-Brown, MD, UCLA;
Peter L. Salgo, MD, Columbia University
Published Online: Tuesday, July 23, 2013
For High-Definition, Click
In the final segment, moderator Peter L. Salgo, MD, asks panelists Jonathan W. Friedberg, MD, Paul A. Hamlin, MD, Craig Moskowitz, MD, and Lauren C. Pinter-Brown, MD, to provide their finals thoughts and main points on the management of patients with Hodgkin lymphoma.

In the future, Pinter-Brown hopes, chemotherapy will no longer be necessary in the management of Hodgkin lymphoma. She hopes that through the utilization of immunotherapy and novel combinations the side effects associated with chemotherapy can be avoided.

The treatment of Hodgkin lymphoma has majorly impacted the care of patients with other types of cancer, Friedberg believes. Furthermore, he adds, the high cure rate in this disease represents one of the biggest victories in medical and radiation oncology. Moving forward, interim imaging and the frontline administration of novel agents will continue to enhance the treatment paradigm. Given this success, a new course has been forged in survivorship care, as patients are now living for decades after their initial diagnosis, Hamlin notes.

The goal in Hodgkin lymphoma is to cure patients with the least amount of treatment, Moskowitz adds. However, if a patient progresses on all standard treatments it is appropriate to administer the older Mustargen Oncovin Procarbazine Prednisone (MOPP) chemotherapy regimen.

View More From This Discussion
Episode 1 Risk-Adapted Approaches in Hodgkin Lymphoma
Episode 2 Optimizing Radiation Therapy in Hodgkin Lymphoma
Episode 3 Reducing Therapy-Related Toxicity in Hodgkin Lymphoma
Episode 4 Management of Hodgkin Lymphoma in Elderly Patients
Episode 5 Primary Management of Advanced Hodgkin Lymphoma
Episode 6 The Role of PET Imaging in Hodgkin Lymphoma
Episode 7 Treating Relapsed and Refractory Hodgkin Lymphoma
Episode 8 Autologous Transplantation in Hodgkin Lymphoma
Episode 9 Utilization of Brentuximab Vedotin in Hodgkin Lymphoma
Episode 10 Allogeneic Transplantation in Hodgkin Lymphoma
Episode 11 Novel Treatment Approaches in Hodgkin Lymphoma
Episode 12 Conclusion: Final Thoughts on Managing Hodgkin Lymphoma
Expert Panelists

Jonathan W. Friedberg, MD

Director, James P. Wilmot Cancer Center
Chief, Hematology/Oncology
Director, Hematological Malignancies Clinical Research, University of Rochester
Rochester, New York

Paul A. Hamlin, MD

Director, Lymphoma Outpatient Activities,
Division of Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Craig H. Moskowitz, MD

Clinical Director, Division of Hematologic Oncology, Attending Physician, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, New York, New York

Lauren C. Pinter-Brown, MD

Clinical Professor of Medicine
The Geffen School of Medicine,
University of California, Los Angeles
Los Angeles, California

Peter L. Salgo, MD

Professor of Medicine and Anesthesiology, Columbia University;
Associate Director of Surgical Intensive Care, New York Presbyterian Hospital
New York, New York
Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading